Investigational Bedtime Drug Modestly Reduces Sleep Apnea
The treatment reduced OSA severity by up to 45% and improved next-day blood pressure in people who also demonstrated a physiological response in upper airway collapsibility.
The treatment reduced OSA severity by up to 45% and improved next-day blood pressure in people who also demonstrated a physiological response in upper airway collapsibility.
Avadel Pharmaceuticals' CEO says the "meaningful increase" in patients initiating therapy underscores the unmet need for a once-at-bedtime therapy.
Takeda announced positive results from a phase 2b trial evaluating TAK-861, an oral orexin receptor 2 agonist, in patients with narcolepsy type 1.
The men experienced serious skin reactions and mouth ulcers after taking drugs indicated for narcolepsy. They had been hoping for cognitive enhancement.
A survey of 1,000 parents in the first half of 2023 reveals how many school-aged children and preteens now take melatonin for sleep.
In a letter to shareholders, the CEO of Swiss clinical-stage biopharmaceutical company NLS Pharmaceutics Ltd recapped the company’s progress and pitfalls for 2023.